Whether to prescribe the embattled agent is the question. What's your answer?
Omnipod 5 System Leads to Significant Glycemic Improvements After Direct Transition from MDI Insulin with CGM
Mean reduction in HbA1c was nearly 1% after transition from MDI plus CGM to Omnipod 5 in the first randomized trial to evaluate the shift in mode of insulin delivery.
Obesity & Type 2 Diabetes: An Expert Discussion
In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.
Cost of Semaglutide, Tirzepatide Prohibitive Despite Significant Benefits
A new economic evaluation estimates that semaglutide would need to drop its current price by 81.9% and tirzepatide by 30.5% to be cost effective.
Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes
"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.
FDA Approves First Rapid-Acting Insulin Biosimilar for Diabetes: Daily Dose
Your daily dose of the clinical news you may have missed.
FDA Approves Merilog, First Rapid-Acting Insulin Biosimilar for Diabetes
Merilog joins two long-acting insulin biosimilar products approved in 2021, bringing the total to three insulin biosimilars available in the United States.
